TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7558212
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oxytocin infusion 10 units in 250 ml of dextrose saline at 125 ml/hr)
Study: 2288128
Drug: Preoperative Co
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative Co 60 gamma teletherapy (part of combined treatment)
Study: 6789851
Drug: Sodium cromoglycate
Normalized name: Sodium cromoglycate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium cromoglycate dry powder inhalation (20 mg/dose)
Study: 6789851
Drug: Metered dose
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metered dose aerosol (2 mg/dose)
Study: 28714728
Drug: Cognitive-behavioral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral therapy (CBT) plus no CM
Study: 23267373
Drug: Medical intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medical intervention (fluticason nasal spray and oral Pseudoephedrin)
Study: 17403076
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg (PPI group)
Study: 17403076
Drug: Cimetidine 800
Normalized name: cimetidine 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 800 mg (H2RA group)
Study: 15110132
Drug: Rofecoxib (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (25 mg) once daily for 7 days
Study: 15110132
Drug: Diclofenac (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (75 mg) once daily for 7 days
Study: 15110132
Drug: Meloxicam (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam (7.5 mg) once daily for 7 days
Study: 9855324
Drug: Levofloxacin 500
Normalized name: levofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin 500 mg once/day for 14 days
Study: 9855324
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg twice/day for 14 days
Study: 3184885
Drug: Marijuana-laced brownies
Normalized name: Lilium brownii var. viridulum bulb extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marijuana-laced brownies (1.6 g of marijuana plant material, 2.8% THC)
Study: 28588109
Drug: Supervised progressive
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supervised progressive exercise therapy (ET)
Study: 25205534
Drug: Very low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Very low-dose INR self-control (VLO group)
Study: 25205534
Drug: Very low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Very low-dose INR self-control (VLT group)
Study: 25205534
Drug: Low-dose INR
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose INR self-control (LOW group)
Study: 15570231
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine infusion at a rate of 6 mL/h
Study: 7494801
Drug: CR tablet
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CR tablet A (acetaminophen A)
Study: 7494801
Drug: CR tablet
Normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CR tablet B (acetaminophen B)
Study: 7494801
Drug: Both CR
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both CR tablets A and B
Study: 31955525
Drug: Anti-EGFR antibody
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-EGFR antibody plus chemotherapy
Study: 31290518
Drug: SC‐FOS‐B (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC‐FOS‐B (combination of spent coffee grounds and fructooligosaccharides)
Study: 11123737
Drug: Sublingual morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual morphine 0.1 mg x kg(‐1)
Study: 11123737
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine 0.1 mg x kg(‐1)
Study: 9882058
Drug: Flamazine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flamazine treatment (standard silver sulfadiazine cream)
Study: 2465709
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg hydromorphone with 1/200,000 epinephrine (N = 15)
Study: 2465709
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg hydromorphone alone (N = 15)
Study: 31856912
Drug: Irinotecan dose-escalated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan dose-escalated FOLFIRI according to UGT1A1 genotyping plus 120 mg regorafenib
Study: 31856912
Drug: 120 mg
Normalized name: papain 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg regorafenib alone
Study: 25557853
Drug: Duloxetine 40
Normalized name: duloxetine 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine 40 mg once a day for a month
Study: 25557853
Drug: Paroxetine 20
Normalized name: PARoxetine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paroxetine 20 mg once a day for a month
Study: 24176253
Drug: Housing First
Approvals — FDA: no, EMA: no, PMDA: no
Description: Housing First with Assertive Community Treatment (HF-ACT)
Study: 17225705
Drug: Multimodality approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodality approach including radiotherapy, chemotherapy, and palliative care for advanced non-small cell carcinoma
Study: 17225705
Drug: Chemotherapy (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (combined with radiotherapy for limited disease) for small cell carcinoma
Study: 55532
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of salbutamol
Study: 9778003
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of salbutamol and intravenous lidocaine
Study: 7980747
Drug: Empirical H2-blocker
Normalized name: capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Empirical H2-blocker treatment (group 2)
Study: 3136677
Drug: alfentanil 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: alfentanil 500 micrograms and midazolam 5 mg
Study: 31238011
Drug: High-sodium meal
Normalized name: bone meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-sodium meal (HSM; 1495 mg Na+)
Study: 31238011
Drug: Low-sodium meal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-sodium meal (LSM; 138 mg Na+)
Study: 25909681
Drug: Fenspiride (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenspiride (80 mg thrice daily)
Study: 25909681
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (antibacterial preparations, topical decongestants, glucocorticoids)
Study: 21888757
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate nasal spray (FFNS) 110 μg once daily for 2 weeks
Study: 17607120
Drug: Docetaxel 35
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 35 mg/m2 IV on days 1, 8, and 15, and cisplatin 80 mg/m2 IV on day 15, every 4 weeks for four cycles
Study: 17607120
Drug: Docetaxel 75
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 IV plus cisplatin 80 mg/m2 IV on day 1 every 3 weeks for four cycles
Study: 9866064
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg aspirin from day 2 of the cycle through pregnancy testing
Study: 9866064
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin (Control)
Study: 7637874
Drug: Yohimbine (alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (alpha 2-adrenergic antagonist)
Study: 7637874
Drug: Morphine (postoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (postoperative intravenous)
Study: 183943
Drug: Propranolol (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (180 and 360 mg daily)
Study: 27185571
Drug: QGE031 (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: QGE031 (240 mg every 2 weeks for 10 weeks)
Study: 16037180
Drug: 3 mL
Normalized name: WATER,INHL 3 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mL of 1.5% lidocaine containing 15 mug of epinephrine IV
Study: 10759733
Drug: Topical anaesthetic
Normalized name: Topical anaesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthetic cream (containing lignocaine and prilocaine) followed by local anaesthetic infiltration
Study: 8613046
Drug: Methotrexate (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate (12.5 mg once weekly for 9 months)
Study: 1358484
Drug: Subcutaneous bolus
Normalized name: subcutaneous bolus insulin patch pump, 200 unit, disposable 2 unit MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous bolus injections of 100 micrograms octreotide every 8 hours
Study: 1358484
Drug: Continuous subcutaneous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous subcutaneous infusion of the same daily dose of octreotide
Study: 1358484
Drug: Both bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both bolus and continuous infusion treatment
Study: 4013628
Drug: Intercostal block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intercostal block (i.c.b.) and centrally acting analgesics on demand
Study: 4013628
Drug: Age-dependent analgesic
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Age-dependent analgesic demand
Study: 4013628
Drug: Duration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duration of treatment with centrally acting analgesics
Study: 27820648
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of traditional Chinese medicine and Western medicine
Study: 17224178
Drug: Daily injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily injectable recombinant GH for 9 months
Study: 16125525
Drug: Fluvastatin (Flu)
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluvastatin (Flu) administered for 6 weeks
Study: 12163783
Drug: C1-inhibitor intravenously
Normalized name: C1 INHIBITOR
DrugBank: Conestat alfa (DB09228)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: C1-inhibitor intravenously in a 1-hr infusion, starting with 6000 IU, followed by 3000 IU, 2000 IU, and 1000 IU at 12-hr intervals
Study: 10357404
Drug: Combined paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Combined paclitaxel (50 mg/m2/dose), cisplatin (15 mg/m2/dose), and etoposide (40 mg/m2/dose) administered twice weekly for 3 weeks, repeated every 28 days.
Study: 10357404
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy with or without concomitant 5-fluorouracil after chemotherapy.
Study: 8951506
Drug: Leflunomide therapy
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Leflunomide therapy
Study: 6189695
Drug: L-tryptophan (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-tryptophan (4 g)
Study: 30902911
Drug: Transversus thoracis
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transversus thoracis muscle plane (TTP) block with 20 mL of either 0.3% or 0.5% ropivacaine bilaterally
Study: 30902911
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (control group, no injections)
Study: 30394494
Drug: Therapeutic hypothermia
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic hypothermia (cold therapy with local sterile frozen ice compress)
Study: 22113535
Drug: Nutraceutical-Combined Pill
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutraceutical-Combined Pill (berberine 500 mg, policosanol 10 mg, red yeast rice 200 mg, folic acid 0.2 mg, coenzyme Q10 2.0 mg, astaxanthin 0.5 mg)
Study: 20017910
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (10 mg of ezetimibe plus 160 mg of fenofibrate)
Study: 20017910
Drug: Atorvastatin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin monotherapy (10 mg)
Study: 17005079
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no additional GTD treatment)
Study: 15357626
Drug: Heberon Alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Heberon Alfa R (formulation A)
Study: 15357626
Drug: Viraferon (formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Viraferon (formulation B)
Study: 11132386
Drug: Artemether-lumefantrine (median
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artemether-lumefantrine (median total dose of 9.6 mg/kg and 57.9 mg/kg of lumefantrine)
Study: 11132386
Drug: Artesunate-mefloquine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Artesunate-mefloquine (12 mg/kg over 3 days and 25 mg/kg)
Study: 27329582
Drug: rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: rivaroxaban (10 mg/d for 14 days beginning 2-3 hours post-operation)
Study: 27329582
Drug: aspirin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: aspirin (100 mg/d for 3 months beginning 2-3 hours post-operation)
Study: 20212251
Drug: Cladribine at
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine at 0.12 mg/kg combined with cyclophosphamide at 250 mg/m2 for 3 days intravenously (CC regimen)
Study: 20212251
Drug: Fludarabine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludarabine at 25 mg/m2 combined with cyclophosphamide at 250 mg/m2 for 3 days intravenously (FC regimen)
Study: 3794876
Drug: Three weekly
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three weekly (tiw) injections of hGH (0.24 IU hGH/kg body weight/wk)
Study: 3794876
Drug: Two weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two weekly (biw) injections of hGH (0.24 IU hGH/kg body weight/wk)
Study: 11728078
Drug: Flurbiprofen (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flurbiprofen (n 12, 2 x 100 mg)
Study: 11728078
Drug: Tiaprofenic acid
Normalized name: tiaprofenic acid
DrugBank: Tiaprofenic acid (DB01600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiaprofenic acid (n 14, 2 x 300 mg)
Study: 31345626
Drug: Chemoradiotherapy (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (two cycles of cisplatin 50 mg/m2 during radiotherapy, followed by four cycles of carboplatin AUC5 and paclitaxel 175 mg/m2)
Study: 25026672
Drug: Weekly Application
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly Application of Pesticide (WAP)
Study: 20093894
Drug: Omega-3 supplement
Normalized name: Systane Vitamin Omega-3 Supplement Softgel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 supplement (1,200 mg eicosapentaenoic acid and 800 mg docosahexaenoic acid)
Study: 16127078
Drug: Doripenem 500
Normalized name: doripenem 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doripenem 500 mg administered over 1 h every 8 h
Study: 16127078
Drug: Prolonged infusions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged infusions of doripenem
Study: 7608317
Drug: Roferon-A reconstituted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roferon-A reconstituted with 10 mg of HSA
Study: 1978736
Drug: Fenoldopam (FD)
DrugBank: Fenoldopam (DB00800)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fenoldopam (FD) at doses from 0.05 to 0.50 micrograms/kg/min
Study: 328540
Drug: Spironolactone and
Normalized name: Spironolactone and torsemide only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone and hydrochlorothiazide combination therapy
Study: 29243273
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for nonsleepy OSA patients (n = 122)
Study: 29243273
Drug: Continuous Positive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous Positive Airway Pressure (CPAP) therapy for sleepy OSA patients (n = 155)
Study: 21898717
Drug: Augmentation strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation strategy
Study: 15186737
Drug: Interferon-alpha 2b,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha 2b, cyclophosphamide, and prednisone as maintenance therapy
Study: 15186737
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no maintenance therapy)
Study: 11297816
Drug: Ketamine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine (0.5 mg/kg over 60 min)
Study: 9043726
Drug: Lorazepam (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (0.03 mg.kg‐1 sl), morphine (0.15 mg.kg‐1 im), and perphenazine (0.05 mg.kg‐1 im)
Study: 9043726
Drug: Lorazepam (0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam (0.03 mg.kg‐1 sl) and saline (1.5 ml im)
Study: 7709624
Drug: Single procedure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single procedure of manual therapy
Study: 28207529
Drug: Dexmedetomidine without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine without loading dose (PRDo)
Study: 28207529
Drug: Propofol/remifentanil/Ringer solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol/remifentanil/Ringer solution (PRR)
Study: 28207529
Drug: Dexmedetomidine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine with loading dose (PRDw)
Study: 17315426
Drug: Patient-controlled epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled epidural analgesia with pethidine (25 mg of five mg/ml solution, lockout of 10 minutes, maximum dose of 150 mg/four hours)
Study: 17315426
Drug: Nurse-administered epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nurse-administered epidural pethidine (bolus of 50 mg, maximum dose of 50 mg/two hours)
Study: 14626183
Drug: Astragalus injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astragalus injection (AI) combined with chemotherapy
Study: 8962554
Drug: Medication alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication alone (simvastatin)
Study: 3842611
Drug: All contrast
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All contrast agents
Study: 27791254
Drug: AGV with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGV with adjunctive triamcinolone (TA group)
Study: 24686255
Drug: Fasinumab 0.03
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasinumab 0.03 mg/kg
Study: 19443679
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg and Ezetimibe 10 mg
Study: 17877648
Drug: Inhaled human
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled human insulin (Exubera; EXU)
Study: 15077226
Drug: Amifostine (740
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (740 mg/m2 for 2 doses preceding BCNU)
Study: 12453890
Drug: 0.3 mU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mU · kg1 · min‐1 insulin infusion
Study: 2246576
Drug: Rifampicin locally
Normalized name: rifampicin
DrugBank: Rifampin (DB01045)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rifampicin locally (ointment)
Study: 6446852
Drug: Immediate Treatment
Normalized name: Aquaphor Immediate Relief Lip Balm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate Treatment Group (Acupuncture)
Study: 6446852
Drug: Delayed Treatment
Normalized name: GRANULES, DELAYED RELEASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed Treatment Group (Acupuncture after initial control)
Study: 6446852
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (Immediate and Delayed Treatment)
Study: 6446852
Drug: Inadequate Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inadequate Treatment Group (Control)
Study: 22684355
Drug: Budesonide 400
Normalized name: Budesonide 400 microgram/actuation powder for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400 mcg twice daily
Study: 20332245
Drug: GH therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH therapy for 4 months (36 microg/kg x d)
Study: 20332245
Drug: Delayed start
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed start of GH therapy (untreated for 4 months, then GH for 4 months)
Study: 18564796
Drug: Ephedrine (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine (initial dose 50 mg infused over 30 minutes, dose intervals of 5 mg)
Study: 18564796
Drug: Mephentermine (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mephentermine (initial dose 50 mg infused over 30 minutes, dose intervals of 5 mg)
Study: 15373702
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication (treated with omeprazole and antibiotics)
Study: 8195678
Drug: Prinomide (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prinomide (1500 mg/day)
Study: 8195678
Drug: Naproxen (1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (1500 mg/day)
Study: 2977043
Drug: Oral dose
Normalized name: Exactamed Oral Dose Syringe 35cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of 3 X 100 mg MPA
Study: 2977043
Drug: Weekly changing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly changing scheme with 2 X 10 mg Tamoxifen and 3 X 100 mg MPA
Study: 2977043
Drug: Oral dose
Normalized name: Exactamed Oral Dose Syringe 35cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of 1000 mg MPA daily (in 4 patients with ovarian carcinoma)
Study: 28986606
Drug: Breviscapine (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breviscapine (120 mg daily, 40 mg three times a day for 14 days)